In a subgroup of patients with KRAS G12C–induced advanced NSCLC who were treated daily with oral sotorasib in a phase II trial, 37.1% exhibited objective, 3.2% complete, and 33.9% partial responses, with a medium duration of 11.1 months (25). Here, KRAS is linked to non-small cell lung carcinoma.